|
insulin resistance |
12 |
|
adiponectin |
11 |
|
animals |
10 |
|
humans |
10 |
|
obesity |
10 |
|
adipocytes - metabolism |
8 |
|
alzheimer's disease |
8 |
|
ampk |
8 |
|
aβ |
8 |
|
chemicals and cas registry numbers |
8 |
|
cognitive impairments |
8 |
|
male |
8 |
|
a-fabp |
7 |
|
dpp4 inhibitor |
7 |
|
female |
7 |
|
fib-4 |
7 |
|
hepatocytes - metabolism |
7 |
|
inflammation |
7 |
|
mice |
7 |
|
mice, inbred c57bl |
7 |
|
nfs |
7 |
|
sglt2 inhibitor |
7 |
|
adaptor protein |
6 |
|
adaptor proteins, signal transducing - genetics - metabolism |
6 |
|
adipose tissue |
6 |
|
adult |
6 |
|
advanced glycation end-products |
6 |
|
aged |
6 |
|
arginine methylation |
6 |
|
blood glucose - metabolism |
6 |
|
blood pressure |
6 |
|
blood–brain barrier |
6 |
|
body mass index |
6 |
|
cancer metabolism |
6 |
|
cell membrane - metabolism |
6 |
|
diabetes |
6 |
|
diabetes mellitus, type 2 - blood - drug therapy |
6 |
|
double-blind method |
6 |
|
enzyme-linked immunosorbent assay |
6 |
|
gluconeogenesis |
6 |
|
glyburide - therapeutic use |
6 |
|
glycolysis |
6 |
|
hepatocellular carcinoma |
6 |
|
hypoglycemic agents - therapeutic use |
6 |
|
ischaemic stroke |
6 |
|
jnk/c-jun signalling |
6 |
|
liver cancer |
6 |
|
macrophages |
6 |
|
middle aged |
6 |
|
mmp-9 |
6 |
|
ph domain and leucine zipper containing 1 (appl1) |
6 |
|
phosphotyrosine interaction |
6 |
|
pkm2 |
6 |
|
ppar gamma - agonists - metabolism |
6 |
|
prmt6 |
6 |
|
proto-oncogene proteins c-akt - metabolism |
6 |
|
rage |
6 |
|
receptors, immunologic - blood - drug effects |
6 |
|
signal transduction |
6 |
|
soluble receptor for advanced glycation end-products |
6 |
|
thiazolidinedione |
6 |
|
thiazolidinediones - therapeutic use |
6 |
|
tnf receptor-associated factor 6 - genetics - metabolism |
6 |
|
type 2 diabetes mellitus |
6 |
|
ubiquitination |
6 |
|
warburg effect |
6 |
|
3t3-l1 cells |
5 |
|
adenoviridae - genetics |
5 |
|
adipocyte |
5 |
|
adipocyte fatty-acid-binding protein |
5 |
|
adipokines |
5 |
|
adiponectin - biosynthesis - metabolism |
5 |
|
adiponectin - blood - genetics - metabolism |
5 |
|
adiponectin - deficiency - therapeutic use |
5 |
|
adiponectin and adipokine |
5 |
|
adiponectin receptor |
5 |
|
adipose tissue - drug effects - metabolism |
5 |
|
aging |
5 |
|
anoxia - metabolism |
5 |
|
blood glucose - drug effects |
5 |
|
cardiac dysfunction |
5 |
|
cell aging - drug effects - physiology |
5 |
|
depression-like behavior |
5 |
|
diabetes mellitus, type 2 - blood - drug therapy - metabolism |
5 |
|
dietary fats - administration & dosage |
5 |
|
disease models, animal |
5 |
|
endothelial cells - drug effects - metabolism - physiology |
5 |
|
endothelial nitric oxide synthase/nitric oxide (enos/no) pathway |
5 |
|
fibrinolytic agents - pharmacology - therapeutic use |
5 |
|
gene expression regulation |
5 |
|
genetic vectors |
5 |
|
hippocampal neurogenesis |
5 |
|
hyperglycemia |
5 |
|
hyperglycemia - diagnosis |
5 |
|
hypoglycemic agents - pharmacology - therapeutic use |
5 |
|
hypoxia |
5 |
|
ischaemic heart disease |
5 |
|
metabolism |
5 |
|
mice, knockout |
5 |
|
myocardial ischaemia/reperfusion |
5 |
|
obesity - blood - diagnosis |
5 |
|
obesity - blood - metabolism |
5 |
|
oncogene proteins - blood |
5 |
|
physical exercise |
5 |
|
plasminogen activator inhibitor 1 - biosynthesis |
5 |
|
plasminogen activator inhibitor 1 - blood - genetics - metabolism |
5 |
|
proto-oncogene proteins - blood |
5 |
|
reactive oxygen species - metabolism |
5 |
|
recombinant proteins - metabolism |
5 |
|
rna, messenger - metabolism |
5 |
|
serpin e2 |
5 |
|
serpins - blood - metabolism |
5 |
|
stem cells - drug effects - metabolism - physiology |
5 |
|
sulfonylurea compounds - pharmacology - therapeutic use |
5 |
|
thiazolidinediones - pharmacology - therapeutic use |
5 |
|
thrombotic dieases |
5 |
|
transduction, genetic |
5 |
|
treatment outcome |
5 |
|
active transport, cell nucleus - drug effects |
4 |
|
adipokine |
4 |
|
adiponectin - chemistry |
4 |
|
adiponectin - genetics - pharmacology |
4 |
|
adiponectin - metabolism |
4 |
|
amp-activated protein kinases - metabolism |
4 |
|
apoptosis - drug effects |
4 |
|
atherosclerosis |
4 |
|
beta catenin - metabolism |
4 |
|
breast neoplasms - metabolism - pathology - therapy |
4 |
|
cardiovascular diseases |
4 |
|
cattle |
4 |
|
cell cycle - drug effects |
4 |
|
cell line |
4 |
|
cell line, tumor |
4 |
|
cell movement - drug effects |
4 |
|
cell nucleus - drug effects - metabolism |
4 |
|
cell proliferation - drug effects |
4 |
|
culture media - chemistry - pharmacology |
4 |
|
cyclin d1 - metabolism |
4 |
|
diabetes mellitus, experimental - drug therapy - metabolism |
4 |
|
endothelium, vascular - drug effects - metabolism - physiology |
4 |
|
fetal blood |
4 |
|
gene therapy - methods |
4 |
|
glycogen synthase kinase 3 - antagonists & inhibitors - metabolism |
4 |
|
glycosylation |
4 |
|
hepatic stellate cells |
4 |
|
jnk |
4 |
|
kupffer cells |
4 |
|
liver fibrosis |
4 |
|
liver sinusoidal endothelial cells |
4 |
|
lysine - chemistry |
4 |
|
mice, nude |
4 |
|
mutagenesis, site-directed |
4 |
|
non-alcoholic steatohepatitis |
4 |
|
phosphorylation - drug effects |
4 |
|
protein processing, post-translational |
4 |
|
protein structure, tertiary |
4 |
|
rats |
4 |
|
signal transduction - drug effects |
4 |
|
tgfβ1 |
4 |
|
xenograft model antitumor assays - methods |
4 |
|
adipocyte fatty acid-binding protein |
3 |
|
amino acid sequence |
3 |
|
astragalus extract |
3 |
|
autoimmune diabetes |
3 |
|
autoimmunity |
3 |
|
blotting, southwestern |
3 |
|
calycosin |
3 |
|
cardiovascular disease |
3 |
|
dimerization |
3 |
|
down-regulation |
3 |
|
electrophoretic mobility shift assay |
3 |
|
endocrinology |
3 |
|
fibroblast growth factors - biosynthesis |
3 |
|
gene regulation |
3 |
|
gip |
3 |
|
gonadotropin-releasing hormone ii |
3 |
|
growth hormone - metabolism |
3 |
|
human growth hormone - metabolism |
3 |
|
hypertriglyceridemia |
3 |
|
immunoglobulin enhancer binding protein |
3 |
|
innate immunity |
3 |
|
intestine |
3 |
|
lipocalin-2 |
3 |
|
liver - metabolism |
3 |
|
medical sciences |
3 |
|
metabolic syndrome |
3 |
|
neutrophil elastase |
3 |
|
nf-κb subunit p65 |
3 |
|
pancreas |
3 |
|
pituitary gland - metabolism |
3 |
|
progesterone receptor |
3 |
|
promoter regions, genetic - drug effects |
3 |
|
promoter regions, genetic - genetics |
3 |
|
ranidae - genetics - metabolism |
3 |
|
receptors, lhrh - biosynthesis - genetics |
3 |
|
receptors, lhrh - genetics |
3 |
|
receptors, retinoic acid - physiology |
3 |
|
receptors, vasoactive intestinal peptide - chemistry - genetics - metabolism |
3 |
|
retinoic acid receptors |
3 |
|
retinoid x receptor alpha - physiology |
3 |
|
silencer |
3 |
|
transcription factor ii d |
3 |
|
transcription factor rela - physiology |
3 |
|
transcriptional regulation |
3 |
|
tretinoin - pharmacology |
3 |
|
adipose-brain axis |
2 |
|
base sequence |
2 |
|
binding sites |
2 |
|
blood-brain barrier |
2 |
|
brain health |
2 |
|
depression |
2 |
|
dna-binding proteins - chemistry - genetics - physiology |
2 |
|
evolution, molecular |
2 |
|
exons |
2 |
|
genetic regulation. |
2 |
|
goldfish - genetics |
2 |
|
gonadotropin-releasing hormone - analogs and derivatives - genetics - metabolism |
2 |
|
high-fat diet |
2 |
|
hormone receptors. |
2 |
|
insulin |
2 |
|
insulin. |
2 |
|
ischemic stroke |
2 |
|
lipid |
2 |
|
liver |
2 |
|
luteinizing hormone releasing hormone. |
2 |
|
neurodegeneration |
2 |
|
neuroinflammation |
2 |
|
peptide hormones |
2 |
|
phospholipase |
2 |
|
promoters (genetics) |
2 |
|
receptors, glucagon - genetics - metabolism |
2 |
|
regulatory sequences, nucleic acid |
2 |
|
reperfusion injury |
2 |
|
repressor proteins - physiology |
2 |
|
transcription factors - chemistry - genetics - physiology |
2 |
|
transcription, genetic |
2 |
|
antibody therapy |
1 |
|
apolipoprotein b (apob) |
1 |
|
intracranial hemorrhage |
1 |
|
metabolic associated fatty liver |
1 |
|
murine double minute 2 (mdm2) |
1 |
|
triglyceride-vldl |
1 |
